Allison N Martin1, Allison Silverstein2,3,4, Robinson Ssebuufu5, Joseph Lule6, Pacifique Mugenzi6, Alexandra Fehr7, Tharcisse Mpunga8, Lawrence N Shulman7,9, Paul H Park3,7,10, Ainhoa Costas-Chavarri2,3,6. 1. Department of Surgery, University of Virginia, Charlottesville, Virginia. 2. Department of Plastic Surgery, Boston Children's Hospital, Boston, Massachusetts. 3. Program in Global Surgery and Social Change, Harvard Medical School, Boston, Massachusetts. 4. Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas. 5. Department of Surgery, Centre Hospitalier Universitaire de Butare, Butare, Rwanda. 6. Department of Surgery, Rwanda Military Hospital, Kigali, Rwanda. 7. Partners In Health/Inshuti Mu Buzima, Kigali, Rwanda. 8. Ministry of Health, Kigali, Rwanda. 9. Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennyslavia. 10. Department of Global Health and Social Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Abstract
BACKGROUND: Gastric cancer is the fifth most common cancer in Eastern Africa. Diagnostic delays in low-resource countries result in advanced disease presentation. We describe perioperative management of gastric cancer in Rwanda. METHODS: A retrospective review of records at three hospitals was performed to identify gastric adenocarcinoma cases from January 2012 to June 2016. Multiple perioperative and tumor-related variables were collected. Descriptive and bivariate analyses were performed. RESULTS: The final analysis included 229 patients with gastric cancer. Median age was 58 years (interquartile range [IQR] 49-65) and 49.6% were female (n = 114). Patients reported symptoms (ie, weight loss, epigastric pain) for a median time of 12 months (IQR 7.5-24). On presentation, 18.8% ( n = 43) had gastric outlet obstruction; 13.5% ( n = 31) had a palpable mass. Fifty-one percent ( n = 117) underwent an operation; of these, 74% ( n = 86) received gastrojejunostomy or were inoperable; and 29% ( n = 34) underwent curative resection. Palliative care referrals were made for 9% ( n = 20). Pathology reports were available for 190 patients (83.0%). Only 11.3% ( n = 26) had Helicobacter pylori ( H. pylori) testing of which 65.4% tested positive ( n = 17). CONCLUSIONS: A majority of patients presented with advanced disease. Very few patients had a curative resection. Significant advances in diagnosis and treatment are needed to improve the care of gastric cancer patients in Rwanda.
BACKGROUND:Gastric cancer is the fifth most common cancer in Eastern Africa. Diagnostic delays in low-resource countries result in advanced disease presentation. We describe perioperative management of gastric cancer in Rwanda. METHODS: A retrospective review of records at three hospitals was performed to identify gastric adenocarcinoma cases from January 2012 to June 2016. Multiple perioperative and tumor-related variables were collected. Descriptive and bivariate analyses were performed. RESULTS: The final analysis included 229 patients with gastric cancer. Median age was 58 years (interquartile range [IQR] 49-65) and 49.6% were female (n = 114). Patients reported symptoms (ie, weight loss, epigastric pain) for a median time of 12 months (IQR 7.5-24). On presentation, 18.8% ( n = 43) had gastric outlet obstruction; 13.5% ( n = 31) had a palpable mass. Fifty-one percent ( n = 117) underwent an operation; of these, 74% ( n = 86) received gastrojejunostomy or were inoperable; and 29% ( n = 34) underwent curative resection. Palliative care referrals were made for 9% ( n = 20). Pathology reports were available for 190 patients (83.0%). Only 11.3% ( n = 26) had Helicobacter pylori ( H. pylori) testing of which 65.4% tested positive ( n = 17). CONCLUSIONS: A majority of patients presented with advanced disease. Very few patients had a curative resection. Significant advances in diagnosis and treatment are needed to improve the care of gastric cancerpatients in Rwanda.
Authors: Joseph W Carlson; Evan Lyon; David Walton; Wai-Chin Foo; Amy C Sievers; Lawrence N Shulman; Paul Farmer; Vânia Nosé; Danny A Milner Journal: Am J Surg Pathol Date: 2010-01 Impact factor: 6.394
Authors: R Newton; P J Ngilimana; A Grulich; V Beral; B Sindikubwabo; A Nganyira; D M Parkin Journal: Int J Cancer Date: 1996-03-28 Impact factor: 7.396
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: John G Meara; Andrew J M Leather; Lars Hagander; Blake C Alkire; Nivaldo Alonso; Emmanuel A Ameh; Stephen W Bickler; Lesong Conteh; Anna J Dare; Justine Davies; Eunice Dérivois Mérisier; Shenaaz El-Halabi; Paul E Farmer; Atul Gawande; Rowan Gillies; Sarah L M Greenberg; Caris E Grimes; Russell L Gruen; Edna Adan Ismail; Thaim Buya Kamara; Chris Lavy; Ganbold Lundeg; Nyengo C Mkandawire; Nakul P Raykar; Johanna N Riesel; Edgar Rodas; John Rose; Nobhojit Roy; Mark G Shrime; Richard Sullivan; Stéphane Verguet; David Watters; Thomas G Weiser; Iain H Wilson; Gavin Yamey; Winnie Yip Journal: Lancet Date: 2015-04-26 Impact factor: 79.321
Authors: Michael J Thun; John Oliver DeLancey; Melissa M Center; Ahmedin Jemal; Elizabeth M Ward Journal: Carcinogenesis Date: 2009-11-24 Impact factor: 4.944
Authors: Joseph B Mabula; Mabula D McHembe; Mheta Koy; Phillipo L Chalya; Fabian Massaga; Peter F Rambau; Nestory Masalu; Hyasinta Jaka Journal: World J Surg Oncol Date: 2012-11-27 Impact factor: 2.754
Authors: Violet Kayamba; Julia Butt; Tim Waterboer; Ellen Besa; Naheed Choudhry; Anglin Hamasuku; Peter Julius; Douglas C Heimburger; Masharip Atadzhanov; Paul Kelly Journal: Cancer Med Date: 2020-03-24 Impact factor: 4.452
Authors: Denise Garcia; Julie B Siegel; David A Mahvi; Biqi Zhang; David M Mahvi; E Ramsay Camp; Whitney Graybill; Stephen J Savage; Antonio Giordano; Sara Giordano; Denise Carneiro-Pla; Mahsa Javid; Aaron P Lesher; Andrea Abbott; Nancy Klauber DeMore Journal: Clin Oncol Res Date: 2020-06-26